Dose Estimation Utility in a Population Pharmacokinetic Analysis of Inhaled Δ9-Tetrahydrocannabinol Cannabis Market Products in Occasional and Daily Users
Open Access
- 23 May 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 46 (5) , 672-680
Abstract
Background: Unusually high variability in blood Δ9-tetrahydrocannabinol (THC) concentrations have been observed in subjects inhaling similar cannabis products over similar time periods when consumption is ad libitum. This makes simple gravimetric dose estimation a poor predictor of THC exposure. Population pharmacokinetic analyses of blood THC concentration versus time data are routinely used to estimate pharmacokinetic parameters. The aim of this study was to estimate the inhaled dose of THC in occasional and daily users of high potency market cannabis. Methods: Blood THC concentrations were measured for 135 minutes from 29 participants who either smoked high concentration flower or inhaled concentrates ad libitum during a 15-minute session. Frequent blood samples were obtained over the following 135 minutes. Results: The estimated central and rapidly equilibrating volumes of distribution of a 3-compartment model were 19.9 ± 1.2 and 51.6 ± 4.7 L whereas the intercompartmental clearances were 1.65 ± 0.14 and 1.75 ± 0.10 L/min, respectively. Covariate-adjusted analysis revealed that the estimated inhaled THC dose was considerably less among occasional users compared with daily users. Conclusions: Three-compartment pharmacokinetics of THC did not differ among the 3 user groups, and the early phase (first 135 minutes postinception of inhalation) kinetics were similar to those previously described after smoking low potency cannabis products. Therefore, inhaled THC dose can be estimated from pharmacokinetic data and covariate-driven adjustments can be used to estimate THC doses, based on the participant cannabis usage pattern (occasional versus daily), improving the accuracy of THC exposure estimates compared with those derived from weighed THC content alone.Keywords
Funding Information
- National Institute on Alcohol Abuse and Alcoholism (DA049800)
This publication has 26 references indexed in Scilit:
- A comprehensive physiologically based pharmacokinetic (PBPK) model for nicotine in humans from using nicotine-containing products with different routes of exposureScientific Reports, 2022
- Association of Naturalistic Administration of Cannabis Flower and Concentrates With Intoxication and ImpairmentJAMA Psychiatry, 2020
- Prevalence and forms of cannabis use in legal vs. illegal recreational cannabis marketsInternational Journal of Drug Policy, 2020
- Validation of a multisubstance online Timeline Followback assessmentBrain and Behavior, 2019
- Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use CannabisJAMA Network Open, 2018
- Quantifying cannabis: A field study of marijuana quantity estimation.Psychology of Addictive Behaviors, 2018
- Population Pharmacokinetic Model of THC Integrates Oral, Intravenous, and Pulmonary Dosing and Characterizes Short- and Long-term PharmacokineticsClinical Pharmacokinetics, 2014
- In Search of Physiologically Based Distribution Volume Estimates for MacromoleculesClinical Pharmacology & Therapeutics, 2012
- Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THCDrug and Alcohol Dependence, 2012
- Ways to Fit a PK Model with Some Data Below the Quantification LimitJournal of Pharmacokinetics and Pharmacodynamics, 2001